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1. Introduction 
Macromolecular heparin is a multichain form of 
heparin, the structural integrity of which is depen- 
dent upon a polysaccharide core [ 11. I have postu- 
lated that macromolecular heparin must be 
depolymerized to become biologically active [ 11 
Macromolecular heparin is a potent inhibitor of heart 
lipoprotein lipase (LPL) in vitro [2]. Injected 
macromolecular heparin has a relatively low po- 
tency as an initiator of LPL activity in the blood. 
This activity appears in the blood rather slowly, 
compared with low molecular weight heparins (i.e., 
commercial heparin or enzymically depolymerized 
macromolecular heparin) [2]. These facts support 
the concept that depolymerization precedes the 
release of biologically active heparin from the mast 
cells. To extend this hypothesis it was necessary 
to demonstrate endogenous heparin in rat blood. 
[35S]heparin has been isolated from dog blood 
by the carrier technique [3]. The work has been 
criticised on the grounds that the concentration of 
heparin which was found was well above the limit 
of detection by normal isolation procedures, which 
have failed to show it [4]. In the present work a 
simular experimental approach was made with rats. 
Heparin of relatively low molecular weight was 
recovered, 90% of which was associated with formed 
elements, principally the platelets. 
2. Methods 
Each of eight male Wistar rats (body weights 
241 + 8.0 g) received 2 mc of carrier-free [ 35S] 
166 
sodium sulfate by intraperitoneal injection and was 
exsanguinated by cardiac puncture under ether 
anaesthesia I8 hr later, Blood (total volume 82 ml) 
was collected into one-ninth volume of anticoagu- 
lant (disodium EDTA, 1.5 g per 100 ml 0. 15 M 
NaCl) using plastic syringes, and transferred to plas- 
tic centrifuge tubes. The blood was centrifuged 
(300 g for 20 min) at room temperature and 
platelet-rich plasma removed with a siliconed Pasteur 
pipet. The remaining blood was respun under the 
same conditions and more platelet-rich plasma removed. 
Platelets were obtained by centrifuging at 2000 g
for 20 min, and platelet-poor plasma pipetted off 
from the plug of platelets. The red blood cells and 
buffy layer were gently resuspended in an equal 
volume of a modified Tyrode’s solution containing 
EDTA but no calcium or magnesium ions [5] and 
centrifuged at 150 g for 20 min. The buffy layer was 
carefully removed with a siliconed Pasteur pipet. 
The platelet and buffy layer preparations were 
resuspended in ethanol. The red blood cells and the 
plasma were each mixed with 3 vol of ethanol. 
After standing overnight at 4°C the four products 
were centrifuged (1000 g for 30 min) at 4°C. The 
supernatants were discarded. The sediments were 
washed with ethanol and hexane at room tempera- 
ture and dried under reduced pressure. Each dry 
product was homogenised with 0.10 M Tri-HCl, 
0.02 M CaCla , pH 8.0 and incubated with shaking 
at 40°C. Pronase (10 mg) was added to each. The 
addition of Pronase was repeated after 24 hr and at 
this time commercial pig mucosal heparin was 
added (5 mg to the red blood cells, 2 mg each to 
the plasma, platelet and huffy layer digests). After 
48 hr heparin was recovered by precipitation with 
cetyl pyridinium chloride in the presence of 1.2 M 
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Fig. 1. Upper panel: elution of carrier pig mucosal heparin and endogenous [35 Slheparin, recovered from rat platelets after 
digestion with Pronase and precipitation with cetyl pyridinium chloride, from a column of microgranular DEAE-cellulose 
(Whatman DE 32, dimensions 1.5 cm X 20 cm, volume 35 ml) with a linear Nail gradient at pH 2.5 [ 11. NaCl concentration 
was determined with a conductivity meter. Lower panel: gel-filtration of samples of macromolecular [” S] heparin from rat skin, 
[35 Slheparin from rat platelets and pig mucosal heparin on a column of Bio-Gel A-15 m agarose gel granules (100-200 mesh, dimen 
sions 1.5 cm X 24 cm, volume 43 ml) equilibrated with 1.0 M NaCl. V, = void volume, determined with tobacco mosaic virus. 
The pig mucosal heparin was quantitated by uranic acid determinations [6] and the rat heparins by measuring 35 S radioactivity. 
NaCl, using general procedures described previously 
[ 11. Each partially purified heparin preparation was 
applied to a column of microgranular DEAEcellu- 
lose (Whatman DE 32) and eluted in a NaClgradient 
at pH 2.5 [ 11. The carrier heparin was measured by 
a carbozole method for uranic acid [6] and endo- 
genous heparin by determining 35 S radioactivity. The 
endogenous and carrier heparins were combined 
and reprecipitated with ethanol. Their relative 
molecular sizes were estimated by gel fdtration on 
a column of Bio-Gel A-l 5 m agarose gel granules. 
To confirm that the endogenous polyanionic 
products were heparins, samples were hydrolysed 
with 0.04 N HCl [7] or degraded with nitrous 
acid [8]. The products of these reactions were 
separated on a column of Sephadex G-25. 
Samples of other 3s S-labelled gly co aminoglycans s 
were recovered from the same rats for comparative 
purposes. Macromolecular heparins were isolated 
from skin [ 1 ] and. peritoneal mast cells [9]. Dermatan 
sulfate, which is the major component of the pre- 
heparin peak eluted from DE 32 in the preparation 
of heparin from rat skin [l] was precipitated as the 
calcium salt from 25% ethanol [lo]. Chondroitin 
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Fig. 2. Gel-filtration of samples of platelet [ 35 Slheparin, skin [ “S] heparin, skin [” Sldermatan sulfate and cartilage [ 35 S]chon- 
droitin sulfate after hydrolysis with 0.04 N HCl at 98°C for 2 hr [ 71. The column of Sephadex G-25 (dimensions 0.9 cm X 50 cm, 
vol 32 ml) was equilibrated with 1.0 M NaCl. The 35S content of each fraction is expressed as a percentage of the total counts in 
the sample. V, = void volume, determined with Blue Dextran 2000. 
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Fig. 3. Gel-filtration of samples of the same four ” S-labeled glycosaminoglycan preparations (see legend to Fig. 2) on the same 
Sephadex G-25 column, after treatment with nitrous acid at room temperature for 90 min [8]. 
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sulfate was recovered from Pronase-digested sternums 
by precipitation from 0.5 M NaCl with cetyl pyri- 
dinium chloride. 
3. Results and Discussion 
The elution of platelet [35 S] heparin and 
carrier pig mucosal heparin from a DE 32 column 
is illustrated in fig. 1 (upper panel). The reason for 
the elution of the heparin at a higher salt concentra- 
tion than the carrier pig mucosal heparin is not 
known, but rat skin heparin shows exactly the same 
behaviour [ 111. 
The elution patterns for gel filtration on Bio-Gel 
A-l 5 m (fig. 1, lower panel) show that the endo- 
genous platelet heparin is larger than pig mucosal 
heparin, but much smaller than macromolecular 
heparin. It is thus of similar size to the lower 
molecular weight fraction obtained by gel filtration 
of enzymically degraded macromolecular heparin [2]. 
Hydrolysis of heparin with 0.04 N HCl yields 
N-desulfated heparin and inorganic sulfate [ 71. The 
gel filtration patterns of hydrolysed platelet and 
skin heparins shown in fig. 2 are virtually identical, 
the material eluting in the void volume being 
N-desulfated heparin. Under the same conditions, 
dermatan sulfate and chondroitin sulfate were 
completely degraded to lower molecular weight 
products. 
N-desulfation of a glucosamine residue in heparin 
with nitrous acid [8] is accompanied by cleavage 
of the adjacent glycosidic bond [ 121. Therefore, more 
low molecular weight products are obtained by 
degradation with nitrous acid than by hydrolysis 
with 0.04 N HCl . Glycosaminoglycans which have 
no N-sulfate groups are resistant to nitrous acid 
under these conditions. Fig. 3 shows gel filtration 
patterns on Sephadex G-25 after nitrous acid 
treatment. The patterns for platelet heparin and 
skin heparin are the same, both having been 
extensively degraded. In contrast, dermatan sulfate 
and chondroitin sulfate were not broken down. 
Thus the presence of N-sulfate in platelet heparin 
in the same proportion found in authentic heparin 
from the skin was established by two different 
methods of degradation. The platelet product there- 
fore meets chemical criteria for heparin. 
I have used the platelet product to illustrate the 
methods used to isolate and characterize the 
endogenous heparin in blood. The reason for this 
is that 50% (in terms of 35 S radioactivity) of the 
heparin recovered was in the platelet product, 30% 
was recovered from the erythrocytes, 10% from the 
buffy layer and 10% from the plasma. Thus 90% 
of the blood heparin was associated with formed 
elements. The high proportion associated with 
platelets is particularly interesting because they 
contain a protein with very high binding affinity 
for heparin, platelet factor 4 [ 131. 
The [35S]heparin radioactivity in blood was 
143 cpm per ml. The specific activities of carrier-free 
heparins recovered from the skin and peritoneal 
mast cells of the same rats were 1100 and 8400 cpm 
per pg uranic acid respectively. Making the possibly 
unwarranted assumption that the specific activity 
of the heparin in blood is within this range, the con- 
centration of heparin in blood can be estimated. By 
these criteria, it is in the range 1.7 to 13 c(g uranic 
acid per 100 ml, 5.5 to 42 pg heparin per 100 ml, 
or, assuming an anticoagulant activity of 160 units 
per mg, 0.88 to 6.7 units per 100 ml. 
With the present experimental design, the use of 
carrier heparin is obligatory. This precludes direct 
chemical analyses and anticoagulant assays of the 
endogenous heparin. Obviously a more direct method 
of determining the concentration of heparin in blood 
is needed. However, this study has demonstrated the 
presence of heparin in blood and its association 
with the formed elements, particularly the platelets. 
Furthermore, the heparin in blood is of relatively 
low molecular weight, supporting the concept that 
depolymerization of the macromolecular form 
probably precedes its release into the blood. 
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